<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:NCBITaxon="http://purl.obolibrary.org/obo/NCBITaxon#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:ncbitaxon="http://purl.obolibrary.org/obo/ncbitaxon#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2006, p. 3665&#8211;3673                                                                                      Vol. 50, No. 11 <br /> 0066-4804/06/$08.00&#11001;0 doi:10.1128/AAC.00555-06 <br /> Copyright &#169; 2006, American Society Microbiology. All Rights Reserved. <br />  <br />  <br />  <br />  Peptide Deformylase Inhibitors Potent Antimycobacterial Agents&#17188;&#8224; <br />    Jeanette W. P. Teo,1&#8225; Pamela Thayalan,1 David Beer,1 Amelia S. L. Yap,1 Mahesh Nanjundappa,1 <br />         Xinyi Ngew,1 Jeyaraj Duraiswamy,1 Sarah Liung,1 Veronique Dartois,1 Mark Schreiber,1 <br />            Samiul Hasan,1 Michael Cynamon,2 Neil S. Ryder,3 Xia Yang,3 Beat Weidmann,3 <br />                      Kathryn Bracken,3 Thomas Dick,1 Kakoli Mukherjee1* <br />        Novartis Institute Tropical Diseases, 10 Biopolis Road, 05-01 Chromos, Singapore 138670, Republic Singapore1; <br />         Central New York Research Corporation, New York, New York2; Novartis Institutes Biomedical Research, <br />                        Inc., Infectious Disease Area, 100 Technology Square, Cambridge, Massachusetts 021393 <br />                              Received 4 May 2006/Returned modification 6 June 2006/Accepted 17 August 2006 <br />  <br />              Peptide deformylase (PDF) catalyzes hydrolytic removal N-terminal formyl group nascent <br />           proteins. <span id='am-152' about='obo:NCBITaxon_169495' typeof='owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_169440 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_7147 obo:NCBITaxon_43733 obo:NCBITaxon_33154 obo:NCBITaxon_43738 obo:NCBITaxon_480117 obo:NCBITaxon_33317 obo:NCBITaxon_169449 obo:NCBITaxon_480118 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_43750 obo:NCBITaxon_33208 obo:NCBITaxon_85512 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_7203 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_33392 obo:NCBITaxon_169455 obo:NCBITaxon_50557 obo:NCBITaxon_43741'><span id='am-153' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-154' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-155' property="rdfs:label" content="This" datatype="xsd:string"></span><span id='am-156'  ></span>This</span> essential step bacterial protein synthesis, making PDF attractive target anti- <br />           bacterial drug development. Essentiality def gene, encoding PDF <span id='am-46' about='obo:NCBITaxon_1763' typeof='obo:NCBITaxon_85007 owl:Thing obo:NCBITaxon_1762 obo:NCBITaxon_1 obo:NCBITaxon_1760 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_2037 obo:NCBITaxon_201174 obo:NCBITaxon_85003'><span id='am-47' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-48' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-49'  ></span><span id='am-50' property="oboInOwl:hasDbXref" content="PMID:7547304" datatype="xsd:string"></span><span id='am-51' property="oboInOwl:hasDbXref" content="PMID:8863452" datatype="xsd:string"></span><span id='am-52' property="oboInOwl:hasDbXref" content="PMID:1380284" datatype="xsd:string"></span><span id='am-53' property="oboInOwl:hasDbXref" content="PMID:2275850" datatype="xsd:string"></span><span id='am-54' property="oboInOwl:hasDbXref" content="PMID:1883713" datatype="xsd:string"></span><span id='am-55' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium Lehmann and Neumann 1896" datatype="xsd:string"></span><span id='am-56' property="oboInOwl:hasDbXref" content="PMID:16014496" datatype="xsd:string"></span><span id='am-57' property="rdfs:label" content="Mycobacterium" datatype="xsd:string"></span><span id='am-58' property="oboInOwl:hasDbXref" content="PMID:7547284" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasDbXref" content="PMID:7907223" datatype="xsd:string"></span><span id='am-60' property="oboInOwl:hasDbXref" content="PMID:1581193" datatype="xsd:string"></span>Mycobacterium</span> tuberculosis, was <br />           demonstrated genetic knockout experiments <span id='am-61' about='obo:NCBITaxon_1765' typeof='obo:NCBITaxon_85007 owl:Thing obo:NCBITaxon_1762 obo:NCBITaxon_1763 obo:NCBITaxon_1 obo:NCBITaxon_1760 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_2037 obo:NCBITaxon_201174 obo:NCBITaxon_85003 obo:NCBITaxon_77643'><span id='am-62' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium tuberculosis typus bovinus" datatype="xsd:string"></span><span id='am-63' property="oboInOwl:hasDbXref" content="PMID:14657105" datatype="xsd:string"></span><span id='am-64' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-65' property="oboInOwl:hasDbXref" content="PMID:10618079" datatype="xsd:string"></span><span id='am-66' property="rdfs:label" content="Mycobacterium bovis" datatype="xsd:string"></span><span id='am-67' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium tuberculosis var. bovis" datatype="xsd:string"></span><span id='am-68' property="oboInOwl:hasDbXref" content="PMID:11931153" datatype="xsd:string"></span><span id='am-69' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-70'  ></span><span id='am-71' property="oboInOwl:hasAlternativeId" content="NCBITaxon:115863" datatype="xsd:string"></span>Mycobacterium bovis</span> BCG. PDF M. tuberculosis <br />           strain H37Rv cloned, expressed, purified N-terminal histidine-tagged recombinant protein in <br />           <span id='am-197' about='obo:NCBITaxon_562' typeof='owl:Thing obo:NCBITaxon_561 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_91347 obo:NCBITaxon_1224 obo:NCBITaxon_2 obo:NCBITaxon_543 obo:NCBITaxon_1236'><span id='am-198' property="oboInOwl:hasRelatedSynonym" content="Bacterium coli commune" datatype="xsd:string"></span><span id='am-199' property="oboInOwl:hasRelatedSynonym" content="Enterococcus coli" datatype="xsd:string"></span><span id='am-200' property="oboInOwl:hasDbXref" content="PMID:10319482" datatype="xsd:string"></span><span id='am-201' property="oboInOwl:hasAlternativeId" content="NCBITaxon:662101" datatype="xsd:string"></span><span id='am-202' property="rdfs:label" content="Escherichia coli" datatype="xsd:string"></span><span id='am-203' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-204' property="oboInOwl:hasRelatedSynonym" content="Escherchia coli" datatype="xsd:string"></span><span id='am-205' property="oboInOwl:hasAlternativeId" content="NCBITaxon:662104" datatype="xsd:string"></span><span id='am-206' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-207' property="oboInOwl:hasRelatedSynonym" content="Bacillus coli" datatype="xsd:string"></span><span id='am-208'  ></span><span id='am-209' property="oboInOwl:hasRelatedSynonym" content="Bacterium coli" datatype="xsd:string"></span><span id='am-210' property="oboInOwl:hasRelatedSynonym" content="Eschericia coli" datatype="xsd:string"></span><span id='am-211' property="oboInOwl:hasRelatedSynonym" content="bacterium E3" datatype="xsd:string"></span><span id='am-212' property="oboInOwl:hasExactSynonym" content="Escherichia/Shigella coli" datatype="xsd:string"></span>Escherichia coli</span>. A novel <span id='am-136' about='obo:NCBITaxon_class' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-137' property="rdfs:label" content="class" datatype="xsd:string"></span><span id='am-138' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>class</span> PDF inhibitors (PDF-I), N-alkyl urea hydroxamic acids, synthesized <br />           evaluated activities M. tuberculosis PDF enzyme antimycobacterial <br />           effects. Several compounds new class 50% inhibitory concentration (IC50) values &lt;100 nM. <br />           Some PDF-I displayed antibacterial activity M. tuberculosis, including MDR strains MIC90 <br />           values &lt;1 &#65533;?&#65533;M. Pharmacokinetic studies potential leads showed compounds orally bio- <br />           available. Spontaneous resistance inhibitors arose frequency &lt;5 &#11547; 10&#11546;7 M. bovis BCG. <br />           DNA sequence analysis spontaneous PDF-I-resistant mutants revealed half mutants had <br />           acquired point mutations formyl methyltransferase gene (fmt), formylated Met-tRNA. The <br />           results study validate M. tuberculosis PDF drug target suggest class compounds <br />           potential developed novel antimycobacterial agents. <br />  <br />  <br />    <span id='am-80' about='obo:NCBITaxon_1773' typeof='obo:NCBITaxon_85007 owl:Thing obo:NCBITaxon_1762 obo:NCBITaxon_1763 obo:NCBITaxon_1 obo:NCBITaxon_1760 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_2037 obo:NCBITaxon_201174 obo:NCBITaxon_85003 obo:NCBITaxon_77643'><span id='am-81' property="rdfs:label" content="Mycobacterium tuberculosis" datatype="xsd:string"></span><span id='am-82'  ></span><span id='am-83' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-84' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-85' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium tuberculosis typus humanus" datatype="xsd:string"></span><span id='am-86' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium tuberculosis var. hominis" datatype="xsd:string"></span><span id='am-87' property="oboInOwl:hasRelatedSynonym" content="Bacterium tuberculosis" datatype="xsd:string"></span><span id='am-88' property="oboInOwl:hasRelatedSynonym" content="Bacillus tuberculosis" datatype="xsd:string"></span>Mycobacterium tuberculosis</span>, pathogen causing 2 million                       active bacterial PDF challenge (51). So far, Ni2&#11001;, <br /> deaths 8 million new cases tuberculosis (TB) year,                    Co2&#11001;, Mn2&#11001; described cations stably <br /> is leading health threat. This fueled human                   replace Fe&#11001;2 retaining high enzymatic activity (25, 49). <br /> immunodeficiency virus epidemic appearance mul-                          Naturally occurring antibiotics, like actinonin, inhibit the <br /> tidrug-resistant TB (17, 18, 46). Infections involving multidrug-                 activity PDF enzyme (2). Based structural (7, 39, 41) <br /> resistant TB harder treat limited efficacy                 mechanistic design, high-throughput screening, <br /> TB control programs (29). This necessitated search                    classes PDF inhibitors (PDF-I) studied <br /> new antituberculosis drugs novel mode action.                           previously (64). Thus far, compounds having hydroxamic <br />    In prokaryotes certain organelles, like plastids mi-                acid-chelating N-formyl hydroxylamine-chelating groups <br /> tochondria eukaryotes, nascent proteins carry N-formylated                  potent enzyme inhibition, good antibacterial activity, <br /> methionine (40). After translational initiation, peptide defor-                   vivo efficacy, including oral activity (9, 12, 27). <br /> mylase (PDF) (EC 3.5.1.27) removes N-formyl group                          In work, validate def (gene encoding PDF) drug <br /> the nascent proteins (42). Deformylated proteins undergo fur-                     target TB proving essentiality Mycobacterium bovis <br /> ther N-terminal processing mature proteins (61). PDF                      BCG. PDF M. tuberculosis strain H37Rv cloned and <br /> is attractive candidate discovery antibacterial                     expressed heterologously E. coli. Recombinant His-tagged <br /> agents, essentiality gene (def) encoding PDF                    M. tuberculosis PDF enzyme purified, biochemical <br /> been shown <span id='am-213' about='obo:NCBITaxon_561' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_91347 obo:NCBITaxon_1224 obo:NCBITaxon_2 obo:NCBITaxon_543 obo:NCBITaxon_1236'><span id='am-214' property="oboInOwl:hasRelatedSynonym" content="Escherchia" datatype="xsd:string"></span><span id='am-215' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-216' property="oboInOwl:hasDbXref" content="PMID:19700542" datatype="xsd:string"></span><span id='am-217' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-218' property="rdfs:label" content="Escherichia" datatype="xsd:string"></span><span id='am-219'  ></span>Escherichia</span> coli <span id='am-28' about='obo:NCBITaxon_1301' typeof='obo:NCBITaxon_91061 owl:Thing obo:NCBITaxon_1239 obo:NCBITaxon_1 obo:NCBITaxon_1300 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_186826'><span id='am-29'  ></span><span id='am-30' property="oboInOwl:hasDbXref" content="PMID:7537076" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-32' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasDbXref" content="PMID:10555340" datatype="xsd:string"></span><span id='am-34' property="rdfs:label" content="Streptococcus" datatype="xsd:string"></span><span id='am-35' property="oboInOwl:hasDbXref" content="PMID:8995803" datatype="xsd:string"></span><span id='am-36' property="oboInOwl:hasDbXref" content="PMID:19620365" datatype="xsd:string"></span><span id='am-37' property="oboInOwl:hasDbXref" content="PMID:14657115" datatype="xsd:string"></span><span id='am-38' property="oboInOwl:hasDbXref" content="PMID:1720654" datatype="xsd:string"></span>Streptococcus</span> pneumoniae                      characterization carried out. Activities novel class of <br /> (8, 36). The enzyme characterized highly unsta-                     PDF-I, N-alkyl urea reverse hydroxamates (27), de- <br /> ble metallopeptidase uses Fe2&#11001; catalytic metal (51).                  termined M. tuberculosis PDF enzyme cell-based <br /> Oxidation Fe2&#11001; inactivates enzyme, purification                     assays antimycobacterial activity. A potent lead, PDF-611 <br />                                                                                   (LBK-611) (15), identified novel antimycobacterial <br />                                                                                   agent. <br />    * Corresponding author. Mailing address: Novartis Institute Trop- <br /> ical Diseases, 10 Biopolis Road, 05-01 Chromos, Singapore 138670, Re- <br />                                                                                                            MATERIALS AND METHODS <br /> public Singapore. Phone: 65-67222923. Fax: 65-67222917. E-mail: <br /> kakoli.mukherjee@novartis.com.                                                      Enzymes, chemicals, antibiotics. Chemicals used highest <br />    &#8225; Present address: National University Hospital, Department                 grade commercially available. Chemicals antibiotics purchased from <br /> Laboratory Medicine, 5 Lower Kent Ridge Road, Main Building,                      Sigma (St. Louis, Mo.), unless indicated. Restriction enzymes and <br /> Level 3, Singapore 119 074, Republic Singapore.                                modifying enzymes purchased New England Biolabs, Inc. (Beverly, <br />    &#8224; Supplemental material article http://aac            Mass.), used according manufacturer&#8217;s recommendations. <br /> .asm.org/.                                                                          Bacterial strains, <span id='am-254' about='obo:NCBITaxon_36549' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_28384'><span id='am-255' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-256' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-257' property="oboInOwl:hasAlternativeId" content="NCBITaxon:2435" datatype="xsd:string"></span><span id='am-258' property="rdfs:label" content="plasmids" datatype="xsd:string"></span>plasmids</span>, media. Bacterial strains plasmids used in <br />    &#17188; <br />      Published ahead print 11 September 2006.                               study listed Table 1. E. coli strains cultured <span id='am-89' about='obo:NCBITaxon_218032' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_33154 obo:NCBITaxon_1206795 obo:NCBITaxon_216294 obo:NCBITaxon_69557 obo:NCBITaxon_69555 obo:NCBITaxon_69556 obo:NCBITaxon_6447 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6448 obo:NCBITaxon_216293 obo:NCBITaxon_6072'><span id='am-90'  ></span><span id='am-91' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-92' property="rdfs:label" content="Luria" datatype="xsd:string"></span><span id='am-93' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Luria</span>-Bertani (LB) <br />  <br />                                                                            3665 <br />  3666       TEO ET AL.                                                                                                            ANTIMICROB. AGENTS CHEMOTHER. <br />  <br />                                                         TABLE 1. Strains plasmids used work <br />   Strain plasmid                                                       Relevant characteristic(s)                                                  Source reference <br />  <br /> Strains <br />   E. coli <br />      XL1-Blue                     recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac &#20851;F&#11032; proAB lacIqZ&#9004;M15 Tn10 (Tetr)&#20852;;                                     Stratagene <br />                                      cloning strain <br />        M15(pREP4)                 Nals Strs Rif s Thi&#11002; Lac&#11002; <span id='am-139' about='obo:NCBITaxon_9225' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1329799 obo:NCBITaxon_1 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_436489 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_9224 obo:NCBITaxon_117571 obo:NCBITaxon_9223 obo:NCBITaxon_33154 obo:NCBITaxon_8782 obo:NCBITaxon_436486 obo:NCBITaxon_1338369 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_8492 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_8825 obo:NCBITaxon_7776 obo:NCBITaxon_436492 obo:NCBITaxon_32561 obo:NCBITaxon_8457 obo:NCBITaxon_436491'><span id='am-140'  ></span><span id='am-141' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-142' property="rdfs:label" content="Ara" datatype="xsd:string"></span><span id='am-143' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Ara</span>&#11001; Gal&#11001; Mtl&#11002; F&#11002; RecA&#11001; Uvr&#11001; Lon&#11001;; expression strain                                      QIAGEN <br />                                      PT5-regulated gene expression <br />  <br />   M. bovis BCG                    Pasteur strain ATCC 35734                                                                                               ATCC <br />    XO22                           Single-crossover strain; Sucs Hygr                                                                                      This work <br />    XOdef                          Single-crossover strain XO22 carrying complementation plasmid pMV262-def                                                This work <br />  <br />  <br /> Plasmids <br />   pCR-XL-TOPO                     Ampr; TA-cloning vector longer PCR products                                                                         Invitrogen <br />   pCR2.1-TOPO                     Ampr; TA-cloning vector                                                                                                 Invitrogen <br />   pQE30                           Ampr; low-copy-number plasmid inducible T5 promoter production N-                                           QIAGEN <br />                                     terminal His6 tag translational fusion <br />   pCR2.1-PDF                      M. tuberculosis def gene cloned pCR2.1-TOPO vector                                                                 This   work <br />   pQE30-PDF                       M. tuberculosis def gene cloned BamHI site pQE30                                                                This   work <br />   pYUB657                         Ampr, Hygr; sacB counterselectable marker, E. coli-Mycobacterium shuttle vector                                         47 <br />   pYUB657-dimer                   DNA fragment containing in-frame def deletion cloned pYUB657 suicide vector                                     This   work <br />   pMV262                          E. coli-Mycobacterium shuttle plasmid, hsp60 promoter; Kanr ColE1 OriM                                                  62 <br />   pMV262-def                      pMV262 containing def gene, expressed translational fusion                                  This   work <br />                                     amino acids hsp60 <br />  <br />  <br />  <br />  <br /> broth (Becton Dickinson, Franklin Lakes, NJ) LB agar plates supplemented             (QIAGEN, <span id='am-230' about='obo:NCBITaxon_195854' typeof='owl:Thing obo:NCBITaxon_186623 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_123369 obo:NCBITaxon_33154 obo:NCBITaxon_1489908 obo:NCBITaxon_123367 obo:NCBITaxon_123368 obo:NCBITaxon_123365 obo:NCBITaxon_123366 obo:NCBITaxon_1489872 obo:NCBITaxon_2759 obo:NCBITaxon_8087 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_28738 obo:NCBITaxon_1489388 obo:NCBITaxon_1489341 obo:NCBITaxon_7776 obo:NCBITaxon_1489913 obo:NCBITaxon_7898 obo:NCBITaxon_195853 obo:NCBITaxon_41665 obo:NCBITaxon_32443'><span id='am-231'  ></span><span id='am-232' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-233' property="rdfs:label" content="Valencia" datatype="xsd:string"></span><span id='am-234' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Valencia</span>, CA). For Southern blot analysis, DNA samples di- <br /> with 100 &#65533;?&#65533;g/ml ampicillin 50 &#65533;?&#65533;g/ml kanamycin cloning             gested appropriate restriction enzyme fragments separated 1% <br /> maintenance. Terrific broth (12 g tryptone, 24 g yeast extract, 4 ml glycerol, 2.3 g     agarose gel transferred Hybond-N&#11001; nylon membrane (Amersham). <br /> potassium phosphate [monobasic], 9.4 g potassium phosphate [dibasic], pH 7.5,            Southern hybridization carried using enhanced chemiluminescence <br /> water make 1 liter) used growth medium expression PDF           direct nucleic acid labeling detection systems (Amersham). <br /> from E. coli.                                                                               Expression purification M. tuberculosis PDF. The M. tuberculosis <br />     M. bovis BCG cultured Middlebrook 7H9 (catalog no. 271310; Difco)             H37Rv genomic DNA sequence (GenBank accession number NC_000962) was <br /> broth supplemented 10% (vol/vol) albumin-dextrose saline (0.81% NaCl,               used design primers 5&#11032;-ATGGATCCATGGCAGTCGTACCCATCCG-3&#11032; <br /> 5% bovine serum albumin fraction V [Roche, Mannheim, Germany], 2%                    5&#11032;-ATGGATCCGTGACCGAACGGGTCGGG-3&#11032;, BamHI sites <br /> glucose), 0.2% glycerol, 0.05% Tween 80 Middlebrook 7H10 (catalog              (underlined) incorporated them. The native TAA stop <span id='am-169' about='obo:NCBITaxon_79338' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_3398 obo:NCBITaxon_4130 obo:NCBITaxon_4069 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91888 obo:NCBITaxon_91827 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_58024 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71274 obo:NCBITaxon_3193'><span id='am-170' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-171'  ></span><span id='am-172' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-173' property="rdfs:label" content="Codon" datatype="xsd:string"></span>codon</span> M. <br /> no. 262710; Difco) agar plates supplemented 10% (vol/vol) oleic acid-               tuberculosis def gene included utilize vector-encoded stop codon, <br /> albumin-dextrose-catalase enrichment (catalog no. 212240; BBL), 0.5% glycerol,           resulting fusion protein MRGSHHHHHHGS-M. tuberculosis PDF-GSAC <br /> and 0.05% Tween 80. When required, hygromycin B (Roche) used                  ELGTPGRPAAKLN, residues italics originating vector. PCR <br /> concentration 50 &#65533;?&#65533;g/ml. Sucrose used 7H10 medium 4%                   carried using high-fidelity Platinum PCR Supermix (Invitrogen, Carls- <br /> concentration.                                                                           bad, CA) according manufacturer&#8217;s protocol. PCR products initially <br />     Buffers. Lysis buffer composed 50 mM HEPES (pH 7.5), 5 mM NiSO4,              cloned pCR2.1-TOPO cloning vector (Invitrogen), generating plasmid <br /> 5 mM MgSO4, 10 &#65533;?&#65533;g/ml catalase, 0.25 mM Tris(2-carboxyethyl)phosphine hy- <br />                                                                                          pCR2.1-PDF; this, def gene subcloned BamHI-linearized E. <br /> drochloride, 10 &#65533;?&#65533;g/ml DNase I, 1 ml protease cocktail inhibitor, 1 mg/ml ly- <br />                                                                                          coli expression vector pQE30 (QIAGEN), generating plasmid pQE30-PDF (Ta- <br /> sozyme, 1% Triton X-100. Buffer I composed 50 mM NaH2PO4, 300 <br />                                                                                          ble 1). Both pCR2.1-PDF pQE30-PDF sequenced. DNA sequences <br /> mM NaCl, 10 mM imidazole, pH 8.0. Buffer II composed 50 mM <br />                                                                                          analyzed using software Vector NTI, version 7.0 (InforMax, Frederick, <br /> NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0. Buffer III com- <br />                                                                                          MD). Amino acid sequence alignments prepared using CLUSTALW, ver- <br /> posed 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0. Gel <br />                                                                                          sion 1.83 (11). All DNA manipulations performed standard condi- <br /> filtration buffer composed 50 mM NaH2PO4, 1 M NaCl, 5% glycerol. <br />                                                                                          tions described previously (55). <br />     Construction BCG def suicide plasmid def complementation <br />                                                                                             E. coli M15(pREP4) cells carrying pQE30-PDF grown terrific broth <br /> plasmid. Gene regions flanking def gene PCR amplified ligated <br />                                                                                          containing 50 &#65533;?&#65533;g/ml kanamycin 100 &#65533;?&#65533;g/ml ampicillin 37&#176;C the <br /> together obtain DNA fragment def gene (636 bp) excluded <br /> in frame (Fig. 1A). Primers BglF (5&#11032;-TGGTAAATAGAGATCTGTGTGCGA                            optical density 600 nm reached &#11011;0.5. The culture induced 0.1 mM <br /> CGTCATAGCCGAGTT-3&#11032;) NdeR (5&#11032;-TGTCTTTTCATATGTAATGGT                                   isopropyl-&#65533;?&#65533;-D-thiogalactopyranoside (IPTG) incubated 37&#176;C addi- <br /> CTCGTGGCCGGGGC-3&#11032;) amplify 1,150-bp fragment upstream def (left                    tional 4 h. Cells (from 1 liter) harvested, cell pellet washed <br /> fragment). Primers NdeFF (5&#11032;-GAAGTGTACATATGGGGCTGAGGAGGC                                 twice sterile phosphate-buffered saline suspended 20 ml lysis buffer. <br /> GGGCAAT-3&#11032;) BglRR (5&#11032;-TTTAATTTTAGATCTGGCGGGCTTTGGC                                   The cells lysed incubation ice 30 min, followed sonication. Cell <br /> ATAGCG-3&#11032;) amplify 1,173-bp fragment downstream def (right fragment).              debris removed centrifugation 35,000 &#11003; g 4&#176;C 15 min. The <br /> Primers BglF/BglRR NdefR/NdeFF carry BglII NdeI restriction sites,               proteins supernatant precipitated adjustment 60% saturation <br /> respectively, enabled left right fragments ligated cloned        ammonium sulfate. The pellet dissolved 10 ml buffer I added <br /> into pCR-XL-TOPO (Table 1). The dimer fragment cloned                  Ni-nitrilotriacetic acid (NTA) slurry (QIAGEN) batch purification by <br /> suicide vector pYUB657 (47), generating def suicide plasmid pYUB657-                 metal affinity chromatography. The resulting mixture incubated 1 h with <br /> dimer (Table 1). The def complementation vector constructed cloning           gentle shaking 4&#176;C. The slurry washed twice buffer II, bound <br /> def gene BamHI site pMV262 (Table 1), generating pMV262-def.                 PDF eluted buffer III. Active fractions obtained Ni-NTA batch <br /> This vector introduced def single-crossover strain allow chromo-           purification purified gel filtration using HiLoad Superdex 26/60 <br /> somal def deleted.                                                                 prep grade column (Amersham) equilibrated gel filtration <br />     Genomic DNA isolation Southern blot analysis. Genomic DNA M.                buffer. Elution buffer flow rate 1 ml/min. The <br /> bovis BCG isolated using protocol described DNeasy tissue kit               active fractions pooled concentrated using Vivaspin 20 centrifugal <br />  VOL. 50, 2006                                                                              PDF INHIBITORS AS ANTIMYCOBACTERIALS                                  3667 <br />  <br />  <br />  <br />  <br />   FIG. 1. (A) Arrangement def neighboring genes M. tuberculosis genome. PCR fragments generated construction def&#9004; <br /> suicide vector indicated solid arrows. See Materials Methods details. The genetic map drawn scale. (B) Southern analysis <br /> of def&#9004; mutants. def&#9004; mutants (lanes 2 4) obtained single-crossover strain complemented, trans, def carried <br /> on plasmid pMV262. Lane 1, wild-type BCG; lane 5, single-crossover strain; lane 6, single-crossover strain XOdef, harboring def gene on <br /> plasmid pMV262-def; lane 7, plasmid pMV262-def; lane M, 1-kb DNA marker. Genomic DNA digested HindIII probed def. <br /> Wild-type BCG yields 10.3-kb fragment, single-crossover strain yields 8.3-kb fragment. Neither fragments seen in <br /> complemented def&#9004; mutants, indicating chromosomal copy def gene deleted. <br />  <br />  <br /> concentrator (Sartorius, Hanover, Germany). Glycerol added final           well. The plates reincubated overnight 37&#176;C. STR used reference <br /> concentration 33% (vol/vol), enzyme stored frozen &#11002;80&#176;C.          drug plate. The MICs obtained quantifying fluorescence of <br />    PDF enzyme assay. The PDF enzyme assay format based published           Alamar Blue, using excitation emission wavelengths 530 nm 590 nm, <br /> method (12), assay carried final volume 50 &#65533;?&#65533;l black,     respectively. Values 150,000 relative fluorescence units considered to <br /> 96-well, half-area plates (Corning Costar, Etobicoke, Ontario, Canada). The         reflect growth. <br /> reaction mixture contained 50 mM HEPES (pH 7.5) &#11011;30 ng E. coli-                 Frequency spontaneous resistant mutants. Log-phase BCG cultures 109 <br /> expressed M. tuberculosis PDF well. The reaction initiated adding        CFU/ml plated 7H10 plates containing drug 10&#11003; MIC onto <br /> N-formyl-methionine-alanine-serine (fMAS) substrate final concentration     drug-free media. Plates incubated 37&#176;C approximately 6 weeks or <br /> 2 mM (Bachem, Germany). The reaction room temperature 2.5           colonies appeared. The frequency spontaneous resistance calculated <br /> min terminated adding 25 &#65533;?&#65533;l fluorescamine (0.02 mg/ml dioxane).        ratio number colonies grew drug-supplemented plates to <br /> The microplate incubated 5 min read fluorescence       drug-free plates. <br /> Tecan Saffire plate reader using excitation wavelength 380 nm             Mutational analyses def fmt genes. The def fmt genes PDF-I- <br /> emission wavelength 470 nm.                                                      resistant BCG mutants analyzed sequence variation. The def gene <br />    Biochemical characterization M. tuberculosis PDF. Biochemical character-      region amplified using primers Updef (5&#11032;-GGTCCCGGTCTTGGTCTGC <br /> ization M. tuberculosis PDF performed using pure batch-purified          A-3&#11032;) Dndef (5&#11032;-CGGCGATGATGCCCGCCG-3&#11032;), generating 838-bp <br /> recombinant enzyme. The effect substrate concentrations M. tuberculosis       amplicon. The primers Upfmt (5&#11032;-TAGCGTGCCTTGCGTACCCA-3&#11032;) and <br /> PDF activity studied using N-formylated peptide substrates, N-formyl-       Dnfmt (5&#11032;-CAGCGCGGGCAACACCAG-3&#11032;) amplify 1,178-bp ampli- <br /> methionine-alanine (fMA) fMAS (Bachem), concentrations ranging             con. High-fidelity PCR carried using Proof Start DNA polymerase <br /> from 0 10 mM. The effects divalent metal ions Ca2&#11001;, Mg2&#11001;, Mn2&#11001;,           (QIAGEN). The PCR products purified agarose gels using a <br /> Co2&#11001;, Cu2&#11001;, Ni2&#11001;, Zn2&#11001; PDF activity assessed addition         QIAquick gel extraction kit (QIAGEN). The purified PCR products se- <br /> different ions final concentration 1 mM assay buffer.                quenced Research Biolabs Technologies (Singapore). Jalview software was <br />    For inhibition studies M. tuberculosis PDF, 30-min preincubation     used visualizing alignment (11), software used for <br /> inhibitor enzyme included prior initiating reaction. The        bioinformatics analysis secondary-structure prediction mutants (13). <br /> concentrations inhibitors varied 0 10 &#65533;?&#65533;M. Fifty percent inhibitory      In vivo pharmacokinetic studies. CD-1 female outbred mice (BioArc, India) <br /> concentration (IC50) values obtained fitting <span id='am-243' about='obo:NCBITaxon_1369087' typeof='obo:NCBITaxon_37567 owl:Thing obo:NCBITaxon_33340 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_85604 obo:NCBITaxon_104431 obo:NCBITaxon_33154 obo:NCBITaxon_37570 obo:NCBITaxon_41191 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_6960 obo:NCBITaxon_33208 obo:NCBITaxon_41196 obo:NCBITaxon_197562 obo:NCBITaxon_85512 obo:NCBITaxon_197563 obo:NCBITaxon_95182 obo:NCBITaxon_41197 obo:NCBITaxon_6656 obo:NCBITaxon_7496 obo:NCBITaxon_7088 obo:NCBITaxon_1206794 obo:NCBITaxon_88770 obo:NCBITaxon_7100 obo:NCBITaxon_33392 obo:NCBITaxon_50557'><span id='am-244' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-245'  ></span><span id='am-246' property="rdfs:label" content="Data" datatype="xsd:string"></span><span id='am-247' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>data</span> sigmoid dose-    used pharmacokinetic studies selected PDF inhibitors. For intrave- <br /> response equation using GraphPad Prism software, version 3.0 (GraphPad Soft-        nous (i.v.) oral (p.o.) administration, compounds formulated 4% <br /> ware, Inc., San Diego, CA).                                                         10% polyethylene glycol 300, respectively. After 1 week acclimation, mice <br />    Antimicrobial agents drug susceptibility testing. Streptomycin (STR),        received dose 1 mg/kg body weight i.v. tail vein injection dose of <br /> isoniazid (INH), rifampin (RIF), linezolid (LZD), erythromycin (ERY)            5 mg/kg p.o. gavage. Groups mice euthanized CO2 inhalation <br /> were obtained Sigma (St. Louis, Mo.). Stock solutions STR, LZD,         different intervals 5 min 4 h following dosing. Blood samples were <br /> ERY prepared 10 mM concentration deionized water, INH,             collected cardiac puncture heparinized tubes. Blood centrifuged, and <br /> RIF, PDF-I dissolved 90% dimethyl sulfoxide. Drug susceptibility        plasma recovered stored frozen &#11002;80&#176;C. Plasma samples ex- <br /> testing based previously published method (20). Logarithmic-phase M.       tracted 1 ml ethyl acetate, analyzed, quantified drug content by <br /> bovis BCG cultures diluted complete 7H9 broth obtain optical          liquid chromatography coupled triple quadrupole mass spectrometry (X- <br /> density 600 nm &#11011;0.04, corresponded approximately 106 CFU/ml,         Terra, C18, 4.6 50 mm, 5 &#65533;?&#65533;m), carbamazepine internal standard. <br /> before added test plate. The plates incubated 37&#176;C 4       For quantitative calibration, standard curves established using spiked com- <br /> days. On fourth day, 50 &#65533;?&#65533;l freshly prepared 1:1 mixture Alamar Blue     pounds plasma. The limit detection 10 ng/ml. A noncompartmental <br /> (Serotec Ltd., Oxford, United <span id='am-240' about='obo:NCBITaxon_kingdom' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-241' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-242' property="rdfs:label" content="kingdom" datatype="xsd:string"></span>Kingdom</span>) 10% Tween 80 added           model (WINNONLIN, version 4.1) used calculate pharmacokinetic pa- <br />  3668       TEO ET AL.                                                                                                 ANTIMICROB. AGENTS CHEMOTHER. <br />  <br />  <br />  <br />  <br />   FIG. 2. Expression M. tuberculosis PDF E. coli. (A) SDS-PAGE analysis PDF expressed E. coli M15(pREP4) carrying pQE30-PDF. <br /> Lane 1, total cell protein uninduced; lane 2, total cell protein induced; lane 3, soluble fraction; lane 4, insoluble fraction; lane 5, Ni-NTA <br /> batch-purified M. tuberculosis PDF; lane 6, M. tuberculosis PDF purified gel filtration; lane M, low-range molecular mass marker (Amersham). <br /> Arrows indicate position recombinant His-tagged PDF. (B) Effects various substrate (fMA fMAS) concentrations recombinant <br /> M. tuberculosis PDF activity. RFU, relative fluorescence units. <br />  <br />  <br />  <br /> rameters. The p.o. bioavailability calculated ratio area   confirmed contained def deletion chromo- <br /> curve (AUC) p.o. administration AUC i.v. administration corrected       (Fig. 1B). When mutants probed def, the <br /> for dose (F &#11005; AUCp.o. &#11003; dosei.v./AUCi.v. &#11003; dosep.o.). <br />                                                                                        chromosomal copy def detected (Fig. 1B). <br />                                                                                            Expression purification M. tuberculosis PDF. As <br />                                   RESULTS                                              shown Fig. 2A, recombinant M. tuberculosis PDF ex- <br />    Essentiality def, gene encoding peptide deformylase                       pressed high levels E. coli. However, expressed pro- <br /> M. bovis BCG. In <span id='am-177' about='obo:NCBITaxon_order' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-178' property="rdfs:label" content="order" datatype="xsd:string"></span><span id='am-179' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>order</span> determine essentiality peptide                        tein largely insoluble form (Fig. 2A, lane 4). Insol- <br /> deformylase M. bovis BCG, two-step allelic-exchange                               ubility recombinant M. tuberculosis PDF reported <br /> methodology (47) employed generate def deletion mu-                             earlier (57). Despite low solubility M. tuberculosis PDF, <br /> tants. A suicide plasmid, pYUB657-dimer (Table 1), elec-                           purification E. coli extracts performed native <br /> troporated BCG, single-crossover strain, XO22,                              conditions. The enzyme purified homogeneity com- <br /> confirmed Southern hybridization (Table 1; Fig. 1B),                            bination ammonium sulfate fractionation, Ni-NTA, gel <br /> obtained. This strain sucrose sensitivity hygromycin                         filtration chromatography. Typical yields 1.2 mg/liter. The <br /> resistance (Sucs Hygr) phenotype conferred inte-                           resulting purified protein showed single band sodium <br /> gration suicide vector chromosome. After                           dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- <br /> second recombination event, selection markers elim-                           PAGE) gels (Fig. 2A, lane 6) showed enzymatic activity on <br /> inated 75 revertant (Sucr Hygs) colonies screened                          N-formylmethionyl peptides. <br /> PCR. All positive chromosomal def. The 28 colonies                                SDS-PAGE analysis (Fig. 2A, lane 6) showed the <br /> that hyg negative PCR analyzed Southern                                purified protein molecular mass &#11011;30 kDa. This was <br /> blotting probing def. Hybridization results showed                        slightly larger predicted molecular mass 23.96 <br /> all recombinants retained wild-type def gene (3.8-kb                        kDa (inclusive His6 tag additional 17 amino <br /> band), single-crossover strain second-                        acids C terminus introduced the <br /> ary recombinants derived generated larger, 4.6-kb frag-                         vector). Such anomalous migration recombinant M. tu- <br /> ment (data shown), suggesting def gene essential                       berculosis PDF observed earlier (57). Analytical gel <br /> and deleted.                                                                 filtration HiLoad Superdex 26/60 prep grade column <br />    A copy def cloned pMV262 (pMV262-def, Kanr [Ta-                             gave apparent molecular mass 24.5 kDa, close that <br /> ble 1]) introduced single-crossover strain XO22,                          deduced amino acid sequence (23.96 kDa). This <br /> resulting transformant XOdef (Table 1). Double crossovers                           suggested peptide deformylase enzyme behaved as <br /> were isolated XOdef culturing strain ab-                            monomeric <span id='am-174' about='obo:NCBITaxon_species' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-175' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-176' property="rdfs:label" content="species" datatype="xsd:string"></span>species</span> native conditions used for <br /> sence hygromycin, allowing integrated vector se-                           purification. Identity 30-kDa protein con- <br /> quence lost. All 28 Sucr Hygs Kmr colonies                            firmed Western blotting using anti-PDF antibody and <br /> selected lost integrated suicide vector. Of these, 25                          anti-His antibody (data shown). <br /> contained wild-type def gene chromosome (data                               There significant loss protein enzyme activity <br /> shown). Southern hybridization remaining isolates                         fractions obtained gel filtration suit- <br />  VOL. 50, 2006                                                                   PDF INHIBITORS AS ANTIMYCOBACTERIALS                3669 <br />  <br />  <br />                          TABLE 2. Effects PDF-I M. tuberculosis PDF H. sapiens PDF enzyme activities <br />                                      (IC50s) antibacterial activities (MIC90s) M. bovis BCG <br />                                                                             IC50 (nM) <br />                                                                                                       MIC90 (&#65533;?&#65533;M) in <br />        Compound                      Structure                                                                              Reference(s) <br />                                                               M. tuberculosis           H. sapiens    M. bovis BCGa <br />                                                                   PDFa                    PDF <br />  <br />  <br />  <br /> Actinonin                                                      50.5 &#11006; 7.7                  43            &#11022;25                   12, 32 <br />  <br />  <br />  <br />  <br /> PDF-709                                                        90.0 &#11006; 4.2                 147a             6.25                27 <br />  <br />  <br />  <br />  <br />                                                                                               a <br /> PDF-611 (LBK-611)                                              69.5 &#11006; 0.7                 115              0.78                15 <br />  <br />  <br />  <br />  <br /> BB-3497                                                        23.9 &#11006; 7.5                    8             3.125               12, 45 <br />  <br />  <br />  <br />  a <br />      This work. <br />  <br />  <br />  <br /> able large-scale screens. Instead, reported earlier E.      lier reports indicated Co2&#11001;, Ni2&#11001;, Zn2&#11001; no <br /> coli PDF (10), batch-purified M. tuberculosis PDF (Fig. 2A,             effect M. tuberculosis PDF enzyme activity (57). <br /> lane 5) used screening large library. After         Enzyme inhibition studies. Several inhibitors avail- <br /> background (induced E. coli M15 cell extracts transformed               able PDF-I library (27) tested M. tuberculosis PDF <br /> with pQE30 vector, treated similar way) sub-               enzyme assay (Table 2). The active compound, PDF-611, <br /> tracted, enzyme activity batch specific         LBK-611 (15), IC50 69.5 nM, similar <br /> could completely inhibited PDF-I. The hits recon-            compound, PDF-709, IC50 90 nM. Two known <br /> firmed using purified enzyme.                                       antibacterial PDF-I, actinonin (10) BB-3497 (12, 14), <br />    Biochemical characterization E. coli-expressed M. <span id='am-248' about='obo:NCBITaxon_36048' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4751 obo:NCBITaxon_40289 obo:NCBITaxon_33154 obo:NCBITaxon_451864 obo:NCBITaxon_147538 obo:NCBITaxon_5185 obo:NCBITaxon_4890 obo:NCBITaxon_716545 obo:NCBITaxon_2759 obo:NCBITaxon_147549'><span id='am-249'  ></span><span id='am-250' property="oboInOwl:hasExactSynonym" content="truffles" datatype="xsd:string"></span><span id='am-251' property="rdfs:label" content="Tuber" datatype="xsd:string"></span><span id='am-252' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-253' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>tuber</span>-          showed potent inhibition M. tuberculosis PDF enzyme, <br /> culosis PDF. Biochemical characterization            IC50s 50.5 23.9 nM, respectively. <br /> pure batch-purified enzyme, results               In order assess issue selectivity, compounds <br /> similar. During optimization substrate concentrations             tested purified <span id='am-157' about='obo:NCBITaxon_9606' typeof='owl:Thing obo:NCBITaxon_9605 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_9526 obo:NCBITaxon_9604 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_117570 obo:NCBITaxon_32525 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_1437010 obo:NCBITaxon_1338369 obo:NCBITaxon_40674 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_314146 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_314293 obo:NCBITaxon_314295 obo:NCBITaxon_376913 obo:NCBITaxon_7776 obo:NCBITaxon_9347 obo:NCBITaxon_207598 obo:NCBITaxon_9443'><span id='am-158' property="oboInOwl:hasExactSynonym" content="man" datatype="xsd:string"></span><span id='am-159'  ></span><span id='am-160' property="rdfs:label" content="Homo sapiens" datatype="xsd:string"></span><span id='am-161' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-162' property="oboInOwl:hasExactSynonym" content="human" datatype="xsd:string"></span><span id='am-163' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Homo sapiens</span> PDF and <br /> fMA fMAS, optimal                 human matrilysin (MMP-7). Matrilysin belongs ma- <br /> substrate M. tuberculosis PDF (Fig. 2B). A prominent fea-           trix metalloproteinase (MMP) <span id='am-111' about='obo:NCBITaxon_family' typeof='owl:Thing NCBITaxon:_taxonomic_rank'><span id='am-112' property="rdfs:label" content="family" datatype="xsd:string"></span><span id='am-113' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>family</span> zinc-containing en- <br /> ture kinetics observed substrates tested       zymes related PDF (44). PDF-611 (LBK-611) PDF- <br /> the enzyme showed saturation kinetics &#11011;10 mM                   709 inhibited H. sapiens PDF IC50s 115 nM 147 <br /> substrate, concentrations 12.5 mM fMAS in-               nM, respectively (Table 2). BB-3497 IC50 8 nM <br /> hibitory M. tuberculosis PDF. This finding similar           H. sapiens PDF (45) actinonin IC50 43 nM <br /> that earlier report (57) (Fig. 2B). Subsequently, 2 mM          (32). However, compounds displayed significant inhibi- <br /> fMAS used evaluating parameters enzyme             tion MMP-7 concentrations 10 &#65533;?&#65533;M inhibited <br /> assays. Velocity versus substrate concentration plots typically         growth K562 cell line concentrations 10 <br /> produced straight line, indicating Km values       &#65533;?&#65533;M, actinonin, IC50 8.5 &#65533;?&#65533;M (data <br /> substrates &#11022;5 mM (data shown).                                  shown). <br />    The enzyme displayed pH optimum 7.5, retaining                Antimycobacterial activities PDF-611 (LBK-611) and <br /> than 20% optimal activity extreme pH, example,         PDF-709. PDF-611 (LBK-611) potent terms of <br /> pH 5.5 pH 10 (data shown). Ionic strength sig-             antimycobacterial activity, MIC90 value 0.78 &#65533;?&#65533;M (0.25 <br /> nificant detrimental effect M. tuberculosis PDF activity          &#65533;?&#65533;g/ml) (Table 2). Both PDF-709 BB-3497 displayed good <br /> concentrations greater 0.1 M KCl (data shown). This            antimycobacterial activities growing M. bovis BCG cul- <br /> result agreed earlier results M. tuberculosis PDF (57).       tures (MIC90s 6.25 &#65533;?&#65533;M 3.125 &#65533;?&#65533;M, respectively); how- <br /> Co2&#11001;, Ni2&#11001;, Zn2&#11001; partially inhibitory, Cu2&#11001;              ever, actinonin showed poor antimycobacterial effect, a <br /> ions completely abolished PDF activity (data shown). Ear-           MIC90 &#11022;25 &#65533;?&#65533;M (&#11022;16 &#65533;?&#65533;g/ml). Based results obtained <br />  3670        TEO ET AL.                                                                                                     ANTIMICROB. AGENTS CHEMOTHER. <br />  <br />  <br />        TABLE 3. MICs PDF-611 (LBK-611) various                                          TABLE 4. Bioinformatics analysis fmt mutants <br />                     M. tuberculosis isolates <br />                                                                                                                                             Predicted within <br />                                                                                                       Mutation    Predicted structural <br />                                                    MIC (&#65533;?&#65533;g/ml)b                          Mutant                                              8 &#197; fMet-tRNA <br />                                                                                                         FMT               locationa <br />           Strain   a <br />                                                                                                                                                 binding sitea <br />                                    PDF-611           BB-3497          Gatifloxacin <br />                                                                                         fmt-100         P100L              Loop                     No <br /> H37Rv (ATCC 27294)              0.125&#8211;0.5          0.125&#8211;0.5           0.03&#8211;0.06        fmt-222a        E222K              <span id='am-131' about='obo:NCBITaxon_6534' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_87862 obo:NCBITaxon_131567 obo:NCBITaxon_6533 obo:NCBITaxon_6527 obo:NCBITaxon_33154 obo:NCBITaxon_1206795 obo:NCBITaxon_216305 obo:NCBITaxon_216366 obo:NCBITaxon_216307 obo:NCBITaxon_977775 obo:NCBITaxon_6447 obo:NCBITaxon_33317 obo:NCBITaxon_6448 obo:NCBITaxon_2759 obo:NCBITaxon_120490 obo:NCBITaxon_6072'><span id='am-132'  ></span><span id='am-133' property="rdfs:label" content="Helix" datatype="xsd:string"></span><span id='am-134' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-135' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Helix</span>                    No <br /> Beijing MDR                        0.125           0.125&#8211;0.25          0.03&#8211;0.06        fmt-53          A53V               Helix                    No <br /> W-Beijing MDR                      0.125              0.125             0.25            fmt-32a         T32N               Loop                     Yes <br /> Beijing F29 MDR                  0.03&#8211;0.25          0.03&#8211;0.5            0.015           fmt-32b         T32N               Loop                     Yes <br /> Inhr SDR                         0.06&#8211;0.125           0.125             0.015           fmt-230         P230S              Loop                     Yes <br /> Strr SDR                            0.5               1.0               0.03            fmt-105         V105F              Sheet                    Yes <br /> Rifr SDR                            0.25              1.2               0.015           fmt-32c         T32N               Loop                     Yes <br /> Pzar SDR                            0.5               1.0               0.03            fmt-192         R192P              Loop                     No <br /> Clinical MDR                     0.06&#8211;1.0           0.06&#8211;2           &#65533;?0.008&#8211;0.06        fmt-276         T276A              Loop                     No <br />                                                                                       fmt-104a        W104L              Loop                     No <br />      MDR, multidrug resistance; SDR, single-drug resistance; Pza, pyrazinamide. <br /> The clinical MDR isolates 10 clinical isolates described MDR;         fmt-104b        W104L              Loop                     No <br /> however, detailed susceptibility pattern TB drugs available.               fmt-117a        G117C              Sheet                    Yes <br />    b <br />      All MIC determinations twice. Single MIC values represent iden-          fmt-124         A124G              Helix                    Yes <br /> tical values experiments, multiple values indicate different results   fmt-222b        E222K              Helix                    No <br /> two experiments. For clinical MDR, multiple values indicate range            fmt-117b        G117C              Sheet                    Yes <br /> MIC values 10 different clinical isolates. <br />                                                                                           a <br />                                                                                             Deduced model M. tuberculosis FMT, based E. coli FMT <br />                                                                                         crystal structure (59). <br />  <br /> from M. tuberculosis PDF inhibition antimycobacterial <br /> studies, compounds PDF-709 PDF-611 (LBK-611) <br /> were selected analyses.                                                     formyl methyltransferase (FMT) mutants mutations <br />    The bactericidal effects PDF-611 (LBK-611) PDF-                               mapped regions active site, deduced a <br /> 709 M. bovis BCG 4 days determined                                 homology model M. tuberculosis FMT based E. coli FMT <br /> time-kill studies (data shown). At 1&#11003; 10&#11003; MIC                              crystal structure (Table 4; Fig. S3 supplemental <br /> for compound, &#65533;?1 log unit decrease viable                             material). <br /> counts, demonstrating bacteriostatic effect time pe-                             For studies mutant strains, fmt-192, fmt-276, fmt- <br /> riod tested. However, increasing incubation time                            104a, fmt-104b characterized growth antimi- <br /> inhibitor, higher bacterial killing observed                            crobial susceptibility, generated against <br /> concentrations (data shown), indicating PDF-I                          PDF-709. Two isolates, fmt-192 fmt-104a, slower dou- <br /> slow acting. PDF-611 (LBK-611) shown effective                           bling times (32 h 35 h, respectively) wild-type M. bovis <br /> against clinical isolates M. tuberculosis. The com-                          BCG (23 h), fmt-276 fmt-104b doubling times <br /> pound demonstrated low MICs (&#65533;?1 &#65533;?&#65533;g/ml) multi-                               (22 h 24 h, respectively) similar wild-type M. <br /> drug-resistant clinical TB isolates (Table 3).                                          bovis BCG (23 h). In MIC testing, FMT mutants were <br />    Spontaneous mutation rates analysis PDF-I-resis-                              16-fold increase MIC (&#11022;100 &#65533;?&#65533;M) <br /> tant M. bovis BCG isolates. The frequency spontaneous                                PDF-611 (LBK-611) PDF-709. However, the <br /> resistance development evaluated using concentration                              mutants retained susceptibility TB drugs, like RIF and <br /> of 10&#11003; MIC. PDF-611- PDF-709-resistant mutants                                      STR, unrelated drugs, like LZD ERY. Target speci- <br /> arose frequencies &#11349;5 &#11003; 10&#11002;7 M. bovis BCG. These                                ficity confirmed expression extra chromo- <br /> mutation frequencies lower development                                 somal copies M. tuberculosis def gene BCG, resulting <br /> resistance INH, occurred frequency 7 &#11003;                                 16-fold increase MIC PDF-611 (LBK-611) (data <br /> 10&#11002;5, higher RIF, &#11011;1 &#11003; 10&#11002;8                                 shown). For comparative purposes, mutant a <br /> (data shown).                                                                       mutation def fmt gene included study. <br />    The development PDF-I resistance bacteria                            This mutant slightly slower doubling time (26 h) than <br /> progress main mechanisms, mutations                             wild-type M. bovis BCG, susceptibility profile similar to <br /> the def gene mutations formyl methyltransferase gene                          fmt mutants. All fmt mutants regained susceptibility <br /> (fmt), catalyzes formylation methionylated initia-                         PDF-I wild-type fmt gene supplied trans, <br /> <span id='am-235' about='obo:NCBITaxon_172918' typeof='owl:Thing obo:NCBITaxon_186623 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_186627 obo:NCBITaxon_186626 obo:NCBITaxon_131567 obo:NCBITaxon_186625 obo:NCBITaxon_117570 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_7952 obo:NCBITaxon_7953 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_32519 obo:NCBITaxon_30727 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_186634 obo:NCBITaxon_1489341 obo:NCBITaxon_7776 obo:NCBITaxon_7898 obo:NCBITaxon_41665 obo:NCBITaxon_32443'><span id='am-236' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-237' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-238' property="rdfs:label" content="Tor" datatype="xsd:string"></span><span id='am-239'  ></span>tor</span> tRNA (12, 21, 34, 35). Twenty-nine spontaneous PDF-I-                               confirming resistance arose mutation fmt <br /> resistant M. bovis BCG mutants characterized. The com-                             (data shown). <br /> plete def fmt genes isolates sequenced.                                Pharmacokinetic studies mice. Clearance PDF-709 <br /> None isolates mutations def gene. Of 29                           PDF-611 (LBK-611) mouse serum measured after <br /> isolates, 16 missense mutations fmt                           compounds administered i.v. p.o. The concentra- <br /> gene (Table 4). In remaining 13 isolates, changes                           tions serum different times used calculate the <br /> detected def fmt genes. It noted indepen-                           corresponding pharmacokinetic parameters presented Table <br /> dently isolated mutants amino acid mutation                                5. PDF-611 (LBK-611) lower half-life (0.5 h) PDF- <br /> (fmt-32a, fmt-32b, fmt-32c T32N mutation; fmt-                              709 (1.6 h) i.v. administration. However, PDF-611 (LBK- <br /> 222a fmt-222b E222K mutation; fmt-117a                              611) higher half-life (3.7 h) PDF-709 (2.7 h) after <br /> fmt-117b G117C mutation). Nonconserved amino acid                               p.o. administration. Both compounds similar bioavailabili- <br /> changes observed half mutants. About half                            ties (&#11011;40%). <br />  VOL. 50, 2006                                                                           PDF INHIBITORS AS ANTIMYCOBACTERIALS                            3671 <br />  <br />  <br />                               TABLE 5. Pharmacokinetic parametersa PDF-611 (LBK-611) PDF-709 mice <br />                              Type            Dose        Cmax                        AUCinf                       CL              Vss       Bioavailability <br />       Compound                                                          Tmax (h)                     t1/2 (h) <br />                            administration      (mg/kg)     (ng/ml)                    (ng &#183; h/ml)                (ml/min/kg)     (liter/kg)        (%) <br />  <br /> PDF-611(LBK-611)                i.v.           1.000        603.6        0.083          253.5        0.500           65.8           3.0 <br />                                 p.o.           5.000        194.3        0.250          566.0        3.70                                           45.0 <br />  <br /> PDF-709                         i.v.           1.000        902.0        0.083          145.6        1.600         114.5            3.9 <br />                                 p.o.           5.000        186.0        0.500          293.0        2.700                                          40.0 <br />   a <br />     Cmax, maximum concentration drug serum; Tmax, time maximum concentration drug serum; AUCinf, area curve extrapolated &#65533;?; t1/2, <br /> half-life; CL, clearance; Vss, volume distribution steady state. <br />  <br />  <br />  <br />  <br />                              DISCUSSION                                            mutations residues important function (by use of <br />                                                                                    homology model E. coli FMT crystal structure) (Table <br />    M. tuberculosis PDF earlier proposed potential drug                    4; Fig. S3 supplemental material) (23, 26, 59). <br /> target (14) BB-3497, PDF inhibitor, potent vitro                    Three independently isolated mutants (fmt-32a, fmt-32b, and <br /> activity M. tuberculosis. The gene encoding M. tubercu-                    fmt-32c [with T32N mutation]) Ser-to-<span id='am-225' about='obo:NCBITaxon_1416571' typeof='owl:Thing obo:NCBITaxon_33208 obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_116706 obo:NCBITaxon_6804 obo:NCBITaxon_131567 obo:NCBITaxon_116704 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_33154 obo:NCBITaxon_72041 obo:NCBITaxon_6681 obo:NCBITaxon_6656 obo:NCBITaxon_6692 obo:NCBITaxon_6682 obo:NCBITaxon_6657 obo:NCBITaxon_1206794 obo:NCBITaxon_6683 obo:NCBITaxon_88770 obo:NCBITaxon_6752 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_553065 obo:NCBITaxon_6072'><span id='am-226' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-227' property="rdfs:label" content="Ala" datatype="xsd:string"></span><span id='am-228' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-229'  ></span>Ala</span> mutation <br /> losis PDF shown genes required <br />                                                                                    region involved recognition initiator tRNA <br /> for optimal growth M. tuberculosis transposon site <br />                                                                                    (53, 54). Mutant fmt-53 (with A53V mutation) lies just <br /> hybridization (56). In work, failure obtain def dele- <br />                                                                                    outside region. Several mutants mutations the <br /> tion mutants M. bovis BCG strongly suggested the <br />                                                                                    C-terminal region involved recognition tRNA by <br /> deletion def lethal. After second recombination <br />                                                                                    FMT obtained (fmt-222a, fmt-222b, fmt-230, fmt- <br /> event, chromosomal wild-type def gene deleted <br />                                                                                    276) (23). Three mutants, fmt-104a fmt-104b (with the <br /> only presence extra chromosomal complementing <br />                                                                                    W104L mutation) fmt-100 (with P100L mutation), <br /> copy def. Taken together, results def <br />                                                                                    mapping close conserved residues (Asn-106, His-108, and <br /> gene essential M. bovis BCG. <br />                                                                                    Asp-144) predicted participate catalytic steps (1, <br />    It observed previously E. coli PDF the <br />                                                                                    28) (see Fig. S3 supplemental material). Without for- <br /> metal ions reaction conditions (substrate type as- <br />                                                                                    mylation assays Met-tRNAfMet, unsure the <br /> say) dramatically change activity properties the <br />                                                                                    extent different fmt mutations affect transformylase <br /> enzyme (10, 38, 49, 50). During biochemical characterization <br />                                                                                    activity. Further studies needed understand func- <br /> of M. tuberculosis PDF, observed differences an <br /> earlier published work (57, 58). These differences possi-                    tional effect mutations. <br /> bly attributed difference assay protocol ex-                         Mutants did mutations def fmt <br /> pression/purification conditions followed study com-                       gene efflux pump mutants, observed E. coli and <br /> pared earlier published work. In earlier work,                      <span id='am-180' about='obo:NCBITaxon_727' typeof='owl:Thing obo:NCBITaxon_135625 obo:NCBITaxon_712 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_1224 obo:NCBITaxon_2 obo:NCBITaxon_1236 obo:NCBITaxon_724'><span id='am-181'  ></span><span id='am-182' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-183' property="oboInOwl:hasRelatedSynonym" content="Haemophilus meningitidis" datatype="xsd:string"></span><span id='am-184' property="rdfs:label" content="Haemophilus influenzae" datatype="xsd:string"></span><span id='am-185' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium influenzae" datatype="xsd:string"></span><span id='am-186' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-187' property="oboInOwl:hasRelatedSynonym" content="Bacterium influenzae" datatype="xsd:string"></span><span id='am-188' property="oboInOwl:hasRelatedSynonym" content="Coccobacillus pfeifferi" datatype="xsd:string"></span><span id='am-189' property="oboInOwl:hasRelatedSynonym" content="Influenza-bacillus" datatype="xsd:string"></span>Haemophilus influenzae</span> (12, 15). However, actual mecha- <br /> investigators purified enzyme presence                       nism resistance mutants remains elucidated. <br /> excess Ni&#11001;2 enzyme activity determined using fMA                        Thus, case mycobacteria, mechanism <br /> the substrate trinitrobenzenesulfonic acid assay (57).                        operative confer resistance PDF-I. <br /> Moreover, assay temperatures different (room                            Recently, eukaryotic PDF enzymes iden- <br /> temperature study versus 30&#176;C previous study).                      tified characterized, e.g., <span id='am-94' about='obo:NCBITaxon_3701' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_980083 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_91827 obo:NCBITaxon_3700 obo:NCBITaxon_131221 obo:NCBITaxon_71240 obo:NCBITaxon_3699 obo:NCBITaxon_58024 obo:NCBITaxon_91836 obo:NCBITaxon_1437201 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_71275 obo:NCBITaxon_3193'><span id='am-95' property="rdfs:label" content="Arabidopsis" datatype="xsd:string"></span><span id='am-96' property="oboInOwl:hasAlternativeId" content="NCBITaxon:45250" datatype="xsd:string"></span><span id='am-97'  ></span><span id='am-98' property="oboInOwl:hasRelatedSynonym" content="Cardaminopsis" datatype="xsd:string"></span><span id='am-99' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-100' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Arabidopsis</span> thaliana (22), <br />    Structure-activity relationship studies actinonin                  <span id='am-114' about='obo:NCBITaxon_5820' typeof='owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_5794 obo:NCBITaxon_131567 obo:NCBITaxon_422676 obo:NCBITaxon_2759 obo:NCBITaxon_5819 obo:NCBITaxon_33630'><span id='am-115' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-116' property="rdfs:label" content="Plasmodium" datatype="xsd:string"></span><span id='am-117'  ></span><span id='am-118' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>Plasmodium</span> falciparum (5), mitochondria H. sapiens <br /> N-alkyl urea hydroxamates (9, 27) indicate efficacious                        (22, 32, 33, 45, 60). The mRNA H. sapiens PDF been <br /> PDF-I share common structural features,                          shown expressed similar levels types human <br /> metal-chelating group, usually hydroxamate/reverse hydrox-                       tissues (22), enzyme active deformylase both <br /> amate, second n-alkyl butyl residue P1&#11032;                    vitro vivo (32, 33, 60). Actinonin to <br /> position mimics methionine chain (4). The PDF-I                      inhibit cell growth various human tumor cell lines in <br /> tested work reverse hydroxamates, carrying                         tumor models (32, 33, 63). In addition, well-characterized <br /> n-butyl residue P1&#11032; position (Table 2). This class                       bacterial PDF inhibitors, BB-3497 actinonin (also used in <br /> compounds inhibit M. tuberculosis PDF IC50s &#65533;?100 nM                        study), inhibit H. sapiens PDF nanomolar concentra- <br /> and bacteriostatic M. bovis BCG, observed                       tions similar bacterial counterpart in- <br /> previously PDF-I <span id='am-1' about='obo:NCBITaxon_1279' typeof='obo:NCBITaxon_91061 owl:Thing obo:NCBITaxon_1385 obo:NCBITaxon_90964 obo:NCBITaxon_1239 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_2'><span id='am-2' property="oboInOwl:hasDbXref" content="PMID:10758876" datatype="xsd:string"></span><span id='am-3'  ></span><span id='am-4' property="oboInOwl:hasDbXref" content="PMID:10319495" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasDbXref" content="PMID:10425778" datatype="xsd:string"></span><span id='am-6' property="rdfs:label" content="Staphylococcus" datatype="xsd:string"></span><span id='am-7' property="oboInOwl:hasDbXref" content="PMID:17220435" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:hasDbXref" content="PMID:9734063" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasRelatedSynonym" content="Aurococcus" datatype="xsd:string"></span><span id='am-11' property="oboInOwl:hasDbXref" content="PMID:10319469" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:hasDbXref" content="PMID:12656157" datatype="xsd:string"></span>Staphylococcus</span> aureus                      hibited (32, 45). <br /> and E. coli (3, 12, 35). The frequency resistance class                    However, despite inhibition cell-free H. sapiens <br /> of inhibitors M. bovis BCG similar previously                    PDF antiproliferative effects tumor cell lines, num- <br /> reported S. aureus (12, 35) E. coli (3, 12).                               ber normal cell lines resistant acti- <br />    Spontaneous PDF-I-resistant isolates M. bovis BCG dem-                       nonin (33) BB-3497 (45). Actinonin tol- <br /> onstrated elevated MICs specifically PDF-I                         erated mice doses 400 mg/kg (24), and <br /> not drug classes. In work, resistance                        successors BB-3497 (BB-83698) tested hu- <br /> arose missense mutations fmt gene 16                      mans levels 475 mg clinically signif- <br /> 29 mutants, rest mutation def                    icant adverse effects (52). Furthermore, recent biochemical <br /> the fmt gene. Several fmt mutants study                      studies H. sapiens PDF showed enzyme had <br />  3672      TEO ET AL.                                                                                                       ANTIMICROB. AGENTS CHEMOTHER. <br />  <br />  <br /> significantly lower activity (kcat/Km) bacterial en-                          Locher, M. G. Page, W. Pirson, G. Rosse, J. L. Specklin. 2000. Hydrox- <br />                                                                                        amic acid derivatives potent peptide deformylase inhibitors antibac- <br /> zyme (E. coli PDF) (32, 33, 45, 52, 60).                                               terial agents. J. Med. Chem. 43:2324&#8211;2331. <br />    In addition, unambiguous localization H. sapiens PDF                    3.   Apfel, C. M., H. Locher, S. Evers, B. Takacs, C. Hubschwerlen, W. Pirson, <br /> in mitochondria important, evidence suggests                        M. G. Page, W. Keck. 2001. Peptide deformylase antibacterial drug <br />                                                                                        target: target validation resistance development. Antimicrob. Agents <br /> mitochondria tumor cells sensitive mito-                             Chemother. 45:1058&#8211;1064. <br /> chondrial insult (6, 48). There examples drugs selectively                 4.   Boularot, A., C. Giglione, I. Artaud, T. Meinnel. 2004. Structure-activity <br /> toxic <span id='am-126' about='obo:NCBITaxon_6754' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_72041 obo:NCBITaxon_33154 obo:NCBITaxon_6681 obo:NCBITaxon_6682 obo:NCBITaxon_6683 obo:NCBITaxon_29964 obo:NCBITaxon_33317 obo:NCBITaxon_2759 obo:NCBITaxon_6072 obo:NCBITaxon_33208 obo:NCBITaxon_116706 obo:NCBITaxon_116704 obo:NCBITaxon_197562 obo:NCBITaxon_197563 obo:NCBITaxon_6656 obo:NCBITaxon_6692 obo:NCBITaxon_1206794 obo:NCBITaxon_6657 obo:NCBITaxon_6753 obo:NCBITaxon_88770 obo:NCBITaxon_6752'><span id='am-127' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-128'  ></span><span id='am-129' property="rdfs:label" content="Cancer" datatype="xsd:string"></span><span id='am-130' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span>cancer</span> cells working inhibition mito-                          relationship analysis therapeutic potential peptide deformylase inhib- <br />                                                                                        itors. Curr. Opin. Investig. Drugs 5:809&#8211;822. <br /> chondrial respiration (19, 43). Mitochondrial membranes                       5.   Bracchi-Ricard, V., K. T. Nguyen, Y. Zhou, P. T. Rajagopalan, D. <br /> less permeable small molecules membranes                            Chakrabarti, D. Pei. 2001. Characterization eukaryotic peptide <br />                                                                                        deformylase <span id='am-119' about='obo:NCBITaxon_5833' typeof='obo:NCBITaxon_5820 owl:Thing obo:NCBITaxon_1 obo:NCBITaxon_5794 obo:NCBITaxon_131567 obo:NCBITaxon_418107 obo:NCBITaxon_422676 obo:NCBITaxon_2759 obo:NCBITaxon_5819 obo:NCBITaxon_33630'><span id='am-120' property="oboInOwl:hasExactSynonym" content="malaria parasite P. falciparum" datatype="xsd:string"></span><span id='am-121' property="rdfs:label" content="Plasmodium falciparum" datatype="xsd:string"></span><span id='am-122'  ></span><span id='am-123' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-124' property="oboInOwl:hasRelatedSynonym" content="Plasmodium (Laverania) falciparum" datatype="xsd:string"></span><span id='am-125' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span>Plasmodium falciparum</span>. Arch. Biochem. Biophys. 396: <br /> and act efficient supplementary filter drugs. For                       162&#8211;170. <br /> this reason, number antibiotics (tetracycline, macrolides,                   6.   Cavalli, L. R., B. C. Liang. 1998. Mutagenesis, tumorigenicity, and <br /> etc.) inhibit mitochondrial targets (16, 30, 31, 37)                          apoptosis: mitochondria involved? Mutat. Res. 398:19&#8211;26. <br />                                                                                   7.   Chan, M. K., W. Gong, P. T. Rajagopalan, B. Hao, C. M. Tsai, D. Pei. <br /> nevertheless currently used human medicine. Thus, acti-                             1997. Crystal structure Escherichia coli peptide deformylase. Bio- <br /> nonin&#8217;s inhibition H. sapiens PDF, resulting mitochon-                           chemistry 36:13904&#8211;13909. <br /> drial disruption, similar tumor specificity (33). A                  8.   Chan, P. F., K. M. O&#8217;Dwyer, L. M. Palmer, J. D. Ambrad, K. A. Ingraham, <br />                                                                                        C. So, M. A. Lonetto, S. Biswas, M. Rosenberg, D. J. Holmes, M. <br /> major, striking difference H. sapiens PDF (also mouse                          Zalacain. 2003. Characterization novel fucose-regulated promoter <br /> PDF) bacterial PDF (E. coli PDF) highly con-                             (PfcsK) suitable gene essentiality antibacterial mode-of-action studies <br />                                                                                        <span id='am-39' about='obo:NCBITaxon_1313' typeof='obo:NCBITaxon_91061 owl:Thing obo:NCBITaxon_1301 obo:NCBITaxon_1239 obo:NCBITaxon_1 obo:NCBITaxon_1300 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_186826'><span id='am-40' property="rdfs:label" content="Streptococcus pneumoniae" datatype="xsd:string"></span><span id='am-41' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-42'  ></span><span id='am-43' property="oboInOwl:hasRelatedSynonym" content="Micrococcus pneumoniae" datatype="xsd:string"></span><span id='am-44' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-45' property="oboInOwl:hasRelatedSynonym" content="Diplococcus pneumoniae" datatype="xsd:string"></span>Streptococcus pneumoniae</span>. J. Bacteriol. 185:2051&#8211;2058. <br /> served EGCLS motif (motif III), leucine mutated into <br />                                                                                   9.   Chen, D., C. Hackbarth, Z. J. Ni, C. Wu, W. Wang, R. Jain, Y. He, K. <br /> glutamic acid mammalian PDF (Glu-173 H. sapiens PDF),                            Bracken, B. Weidmann, D. V. Patel, J. <span id='am-220' about='obo:NCBITaxon_426861' typeof='owl:Thing obo:NCBITaxon_78536 obo:NCBITaxon_1 obo:NCBITaxon_131567 obo:NCBITaxon_4447 obo:NCBITaxon_4747 obo:NCBITaxon_3398 obo:NCBITaxon_1437183 obo:NCBITaxon_33090 obo:NCBITaxon_158332 obo:NCBITaxon_158426 obo:NCBITaxon_73496 obo:NCBITaxon_131221 obo:NCBITaxon_58024 obo:NCBITaxon_58023 obo:NCBITaxon_2759 obo:NCBITaxon_35493 obo:NCBITaxon_158406 obo:NCBITaxon_1437197 obo:NCBITaxon_3193'><span id='am-221' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-222' property="rdfs:label" content="Trias" datatype="xsd:string"></span><span id='am-223' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-224'  ></span>Trias</span>, R. J. White, Z. Yuan. 2004. <br /> which results low activity H. sapiens PDF (60). From                         Peptide deformylase inhibitors antibacterial agents: identification of <br />                                                                                        VRC3375, proline-3-alkylsuccinyl hydroxamate derivative, using in- <br /> the sequence similarity, M. tuberculosis PDF 11% identical                          tegrated combinatorial medicinal chemistry approach. Antimicrob. <br /> overall 6% identity active site H.                            Agents Chemother. 48:250&#8211;261. <br /> sapiens PDF. These differences exploited make com-                     10.   Chen, D. Z., D. V. Patel, C. J. Hackbarth, W. Wang, G. Dreyer, D. C. Young, <br />                                                                                        P. S. Margolis, C. Wu, Z. J. Ni, J. Trias, R. J. White, Z. Yuan. 2000. <br /> pounds decreased affinity H. sapiens PDF                              Actinonin, naturally occurring antibacterial agent, potent deformylase <br /> affecting potency respect M. tuberculosis PDF. In                        inhibitor. Biochemistry 39:1256&#8211;1262. <br /> this study, PDF-I selectivity M. tuber-                  11.   Clamp, M., J. Cuff, S. M. Searle, G. J. Barton. 2004. The Jalview Java <br />                                                                                        alignment editor. Bioinformatics 20:426&#8211;427. <br /> culosis PDF, considered studies                    12.   Clements, J. M., R. P. Beckett, A. Brown, G. Catlin, M. Lobell, S. Palan, W. <br /> to tolerability mice, addition lack effect                    Thomas, M. Whittaker, S. Wood, S. Salama, P. J. Baker, H. F. Rodgers, V. <br />                                                                                        Barynin, D. W. Rice, M. G. Hunter. 2001. Antibiotic activity char- <br /> MMP-7 K562 cell line 10 &#65533;?&#65533;M (&#11011;100-fold-higher                             acterization BB-3497, novel peptide deformylase inhibitor. Antimicrob. <br /> concentration H. sapiens PDF IC50).                                               Agents Chemother. 45:563&#8211;570. <br />    In order ensure treatment compliance, antituberculosis                     13.   Cuff, J. A., G. J. Barton. 1999. Evaluation improvement multiple <br />                                                                                        sequence methods protein secondary structure prediction. Proteins 34: <br /> therapy requires oral dosing regimen day less.                         508&#8211;519. <br /> The oral bioavailabilities PDF-611 (LBK-611) PDF-709                      14.   Cynamon, M. H., E. Alvirez-Freites, A. E. Yeo. 2004. BB-3497, peptide <br /> were range 40% mouse, indicating potential                            deformylase inhibitor, active Mycobacterium tuberculosis. J. An- <br />                                                                                        timicrob. Chemother. 53:403&#8211;405. <br /> oral administration humans. This reinforced                   15.   Dean, C. R., S. Narayan, D. M. Daigle, J. L. Dzink-Fox, X. Puyang, K. R. <br /> relatively long half-lives 3.7 h 2.7 h, respectively, fol-                      Bracken, K. E. Dean, B. Weidmann, Z. Yuan, R. Jain, N. S. Ryder. 2005. <br />                                                                                        Role AcrAB-TolC efflux pump determining susceptibility Hae- <br /> lowing oral administration. Assuming interspecies scaling                              mophilus influenzae novel peptide deformylase inhibitor LBM415. <br /> within normal range, half-life mouse sup-                          Antimicrob. Agents Chemother. 49:3129&#8211;3135. <br /> port once-daily oral dosing humans. These figures constitute                  16.   Vries, H., A. J. Arendzen, A. M. Kroon. 1973. The interference the <br />                                                                                        macrolide antibiotics mitochondrial protein synthesis. Biochim. Bio- <br /> an improvement previous half-life reports PDF inhib-                          phys. Acta 331:264&#8211;275. <br /> itors (27). Oral bioavailabilities PDF-611 (LBK-611)                      17.   Dye, C. 2006. Global epidemiology tuberculosis. Lancet 367:938&#8211;940. <br /> PDF-709 clear improvement reported                     18.   Dye, C., C. J. Watt, D. M. Bleed, S. M. Hosseini, M. C. Raviglione. 2005. <br />                                                                                        Evolution tuberculosis control prospects reducing tuberculosis <br /> other PDF inhibitors class N-alkyl urea hydroxamic acids                        incidence, prevalence, deaths globally. JAMA 293:2767&#8211;2775. <br /> (0.1 3.2%) (27) BB-83698 (i.v. application only)                 19.   Fantin, V. R., M. J. Berardi, L. Scorrano, S. J. Korsmeyer, P. Leder. <br />                                                                                        2002. A novel mitochondriotoxic small molecule selectively inhibits <br /> (52). The total clearance levels moderate com-                           tumor cell growth. Cancer Cell 2:29&#8211;42. <br /> pounds, i.e., 66 114 ml/min/kg PDF-611 (LBK-611)                     20.   Franzblau, S. G., R. S. Witzig, J. C. McLaughlin, P. Torres, G. Madico, A. <br /> PDF-709, respectively, lie range mouse liver                           Hernandez, M. T. Degnan, M. B. Cook, V. K. Quenzer, R. M. Ferguson, and <br />                                                                                        R. H. Gilman. 1998. Rapid, low-technology MIC determination clinical <br /> blood flow (90 ml/min/kg). Thus, group PDF inhibitors                          Mycobacterium tuberculosis isolates using microplate Alamar Blue <br /> has potential developed new class                            assay. J. Clin. Microbiol. 36:362&#8211;366. <br /> antituberculosis agent.                                                          21.   Giglione, C., T. Meinnel. 2001. Resistance anti-peptide deformylase <br />                                                                                        drugs. Expert Opin. Ther. Targets 5:415&#8211;418. <br />                                                                                  22.   Giglione, C., A. Serero, M. Pierre, B. Boisson, T. Meinnel. 2000. Iden- <br />                         ACKNOWLEDGMENTS                                                tification eukaryotic peptide deformylases reveals universality N-termi- <br />                                                                                        nal protein processing mechanisms. EMBO J. 19:5916&#8211;5929. <br />   We thank Sabine Daugelat providing advice knockout pro-             23.   Gite, S., Y. Li, V. Ramesh, U. L. RajBhandary. 2000. Escherichia coli <br /> cedure Marty Pavelka pYUB657. We thank Brigitte Gicquel                    methionyl-tRNA formyltransferase: role amino acids conserved the <br /> providing pJEM15, used overexpression studies.                           linker region C-terminal domain specific recognition the <br />                                                                                        initiator tRNA. Biochemistry 39:2218&#8211;2226. <br />                                                                                  24.   Gordon, J. J., B. K. Kelly, G. A. Miller. 1962. Actinonin: antibiotic <br />                               REFERENCES <br />                                                                                        substance produced actinomycete. Nature 195:701&#8211;702. <br /> 1. Almassy, R. J., C. A. Janson, C. C. Kan, Z. Hostomska. 1992. Structures   25.   Groche, D., A. Becker, I. Schlichting, W. Kabsch, S. Schultz, A. F. <br />    apo complexed Escherichia coli glycinamide ribonucleotide trans-             Wagner. 1998. Isolation crystallization functionally competent Esch- <br />    formylase. Proc. Natl. Acad. Sci. USA 89:6114&#8211;6118.                                 erichia coli peptide deformylase forms containing iron nickel the <br /> 2. Apfel, C., D. W. Banner, D. Bur, M. Dietz, T. Hirata, C. Hubschwerlen, H.           active site. Biochem. Biophys. Res. Commun. 246:342&#8211;346. <br />  VOL. 50, 2006                                                                                 PDF INHIBITORS AS ANTIMYCOBACTERIALS                                    3673 <br />  <br /> 26. Guillon, J.-M., Y. Mechulam, J.-M. Schmitter, S. Blanquet, G. Fayat.               Hydroxamic acids pharmacological agents. Curr. Med. Chem. 9:1631&#8211; <br />     1992. Disruption gene Met-tRNAfMetformyltransferase severely                1653. <br />     impairs growth Escherichia coli. J. Bacteriol. 174:4294&#8211;4301.                 45.   Nguyen, K. T., X. Hu, C. Colton, R. Chakrabarti, M. X. Zhu, D. Pei. <br /> 27. Hackbarth, C. J., D. Z. Chen, J. G. Lewis, K. Clark, J. B. Mangold, J. A.              2003. Characterization human peptide deformylase: implications for <br />     Cramer, P. S. Margolis, W. Wang, J. Koehn, C. Wu, S. Lopez, G. Withers III,            antibacterial drug design. Biochemistry 42:9952&#8211;9958. <br />     H. Gu, E. Dunn, R. Kulathila, S.-H. <span id='am-144' about='obo:NCBITaxon_9596' typeof='owl:Thing obo:NCBITaxon_33213 obo:NCBITaxon_1 obo:NCBITaxon_9526 obo:NCBITaxon_9604 obo:NCBITaxon_32523 obo:NCBITaxon_131567 obo:NCBITaxon_32524 obo:NCBITaxon_117570 obo:NCBITaxon_32525 obo:NCBITaxon_89593 obo:NCBITaxon_7742 obo:NCBITaxon_117571 obo:NCBITaxon_33154 obo:NCBITaxon_1437010 obo:NCBITaxon_1338369 obo:NCBITaxon_40674 obo:NCBITaxon_8287 obo:NCBITaxon_2759 obo:NCBITaxon_314146 obo:NCBITaxon_6072 obo:NCBITaxon_33511 obo:NCBITaxon_33208 obo:NCBITaxon_7711 obo:NCBITaxon_314293 obo:NCBITaxon_314295 obo:NCBITaxon_376913 obo:NCBITaxon_7776 obo:NCBITaxon_9347 obo:NCBITaxon_207598 obo:NCBITaxon_9443'><span id='am-145' property="oboInOwl:hasAlternativeId" content="NCBITaxon:317028" datatype="xsd:string"></span><span id='am-146' property="oboInOwl:hasAlternativeId" content="NCBITaxon:445518" datatype="xsd:string"></span><span id='am-147' property="oboInOwl:hasDbXref" content="GC_ID:1" datatype="xsd:string"></span><span id='am-148' property="oboInOwl:hasExactSynonym" content="chimpanzees" datatype="xsd:string"></span><span id='am-149'  ></span><span id='am-150' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-151' property="rdfs:label" content="Pan" datatype="xsd:string"></span>Pan</span>, W. L. Porter, J. Jacobs, J. Trias,      46.   Nunn, P., B. Williams, K. Floyd, C. Dye, G. Elzinga, M. Raviglione. <br />     D. V. Patel, B. Weidmann, R. J. White, Z. Yuan. 2002. N-Alkyl urea                 2005. Tuberculosis control era HIV. Nat. Rev. Immunol. 5:819&#8211;826. <br />     hydroxamic acids new class peptide deformylase inhibitors           47.   Pavelka, M. S., Jr., W. R. Jacobs, Jr. 1999. Comparison construc- <br />     antibacterial activity. Antimicrob. Agents Chemother. 46:2752&#8211;2764.                    tion unmarked deletion mutations <span id='am-72' about='obo:NCBITaxon_1772' typeof='obo:NCBITaxon_85007 owl:Thing obo:NCBITaxon_1762 obo:NCBITaxon_1763 obo:NCBITaxon_1 obo:NCBITaxon_1760 obo:NCBITaxon_131567 obo:NCBITaxon_2 obo:NCBITaxon_2037 obo:NCBITaxon_201174 obo:NCBITaxon_85003'><span id='am-73' property="oboInOwl:hasDbXref" content="GC_ID:11" datatype="xsd:string"></span><span id='am-74'  ></span><span id='am-75' property="oboInOwl:hasRelatedSynonym" content="Bacillus smegmatis" datatype="xsd:string"></span><span id='am-76' property="rdfs:label" content="Mycobacterium smegmatis" datatype="xsd:string"></span><span id='am-77' property="oboInOwl:hasOBONamespace" content="ncbi_taxonomy" datatype="xsd:string"></span><span id='am-78' property="oboInOwl:hasRelatedSynonym" content="Mycobacterium paratuberculosis smegmatis" datatype="xsd:string"></span><span id='am-79' property="oboInOwl:hasRelatedSynonym" content="Bacterium smegmatis" datatype="xsd:string"></span>Mycobacterium smegmatis</span>, Mycobac- <br /> 28. Klein, C., P. Chen, J. H. Arevalo, E. A. Stura, A. Marolewski, M. S. Warren,           terium bovis bacillus Calmette-Gue&#180;rin, Mycobacterium tuberculosis <br />     S. J. Benkovic, I. A. Wilson. 1995. Towards structure-based drug design:           H37Rv allelic exchange. J. Bacteriol. 181:4780&#8211;4789. <br />     crystal structure multisubstrate adduct complex glycinamide ribonu-      48.   Penta, J. S., F. M. Johnson, J. T. Wachsman, W. C. Copeland. 2001. <br />     cleotide transformylase 1.96 A resolution. J. Mol. Biol. 249:153&#8211;175.               Mitochondrial DNA human malignancy. Mutat. Res. 488:119&#8211;133. <br /> 29. Kremer, L. S., G. S. Besra. 2002. Current status future development      49.   Ragusa, S., S. Blanquet, T. Meinnel. 1998. Control peptide deformylase <br />     antitubercular chemotherapy. Expert Opin. Investig. Drugs 11:1033&#8211;1049.             activity metal cations. J. Mol. Biol. 280:515&#8211;523. <br /> 30. Kroon, A. M., B. H. Dontje, M. Holtrop, C. Van den Bogert. 1984. The         50.   Rajagopalan, P. T., A. Datta, D. Pei. 1997. Purification, characterization, <br />     mitochondrial genetic target chemotherapy: tetracyclines            inhibition peptide deformylase Escherichia coli. Biochemistry <br />     cytostatics. Cancer Lett. 25:33&#8211;40.                                                    36:13910&#8211;13918. <br /> 31. Kroon, A. M., C. Van den Bogert. 1983. Antibacterial drugs         51.   Rajagopalan, P. T., D. Pei. 1998. Oxygen-mediated inactivation pep- <br />     interference biogenesis mitochondria animal human cells.            tide deformylase. J. Biol. Chem. 273:22305&#8211;22310. <br />     Pharm. Weekbl. Sci. 5:81&#8211;87.                                                     52.   Ramanathan-Girish, S., J. McColm, J. M. Clements, P. Taupin, S. Barrowcliffe, <br /> 32. Lee, M. D., C. Antczak, Y. Li, F. M. Sirotnak, W. G. Bornmann, D. A.               J. Hevizi, S. Safrin, C. Moore, G. Patou, H. Moser, A. Gadd, U. Hoch, V. Jiang, <br />     Scheinberg. 2003. A new human peptide deformylase inhibitable acti-                 D. Lofland, K. W. Johnson. 2004. Pharmacokinetics animals humans <br />     nonin. Biochem. Biophys. Res. Commun. 312:309&#8211;315.                                     first-in-class peptide deformylase inhibitor. Antimicrob. Agents Chemother. <br /> 33. Lee, M. D., Y. She, M. J. Soskis, C. P. Borella, J. R. Gardner, P. A. Hayes,           48:4835&#8211;4842. <br />     B. M. Dy, M. L. Heaney, M. R. Philips, W. G. Bornmann, F. M. Sirotnak,       53.   Ramesh, V., S. Gite, Y. Li, U. L. RajBhandary. 1997. Suppressor muta- <br />     D. A. Scheinberg. 2004. Human mitochondrial peptide deformylase, new                 tions Escherichia coli methionyl-tRNA formyltransferase: role 16- <br />     anticancer target actinonin-based antibiotics. J. Clin. Investig. 114:1107&#8211;         amino acid insertion module initiator tRNA recognition. Proc. Natl. Acad. <br />     1116.                                                                                  Sci. USA 94:13524&#8211;13529. <br /> 34. Margolis, P., C. Hackbarth, S. Lopez, M. Maniar, W. Wang, Z. Yuan, R.            54.   Ramesh, V., S. Gite, U. L. RajBhandary. 1998. Functional interaction of <br />     White, J. Trias. 2001. Resistance Streptococcus pneumoniae                   arginine conserved sixteen amino acid insertion module Esch- <br />     deformylase inhibitors mutations defB. Antimicrob. Agents                 erichia coli methionyl-tRNA formyltransferase determinants formyl- <br />     Chemother. 45:2432&#8211;2435.                                                               ation initi <br /> </body></html>